Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.04 is 108% above its 5-year average of -0.55, near the high end of its 5-year range (-3.51–0.66).
As of the fiscal period ended Tuesday, June 30, 2026. 40.86% below its 12-month average of 0.07.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.04.
DEBT TO EQUITY RATIO
0.04
DEBT TO EQUITY RATIO AVG TTM
0.07
DEBT TO EQUITY RATIO AVG 3Y
0.10
DEBT TO EQUITY RATIO AVG 5Y
-0.55
DEBT TO EQUITY RATIO AVG 10Y
-0.33
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-40.86%
CURRENT VS 3Y AVG
-53.90%
CURRENT VS 5Y AVG
+108.03%
CURRENT VS 10Y AVG
+113.27%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
-68.34%
vs the sector median at left
BioStem Technologies, Inc.
Market Cap
$43.82M
Debt to Equity Ratio
0.04
TTM Avg
0.07
3Y Avg
0.10
5Y Avg
-0.55
Market Cap
$45.15M
Debt to Equity Ratio
0.00
TTM Avg
0.45
3Y Avg
0.37
5Y Avg
0.27
Market Cap
$45.37M
Debt to Equity Ratio
0.59
TTM Avg
0.44
3Y Avg
0.44
5Y Avg
0.29
Market Cap
$47.01M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.13
5Y Avg
0.14
Market Cap
$41.60M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$40.28M
Debt to Equity Ratio
0.34
TTM Avg
0.23
3Y Avg
0.23
5Y Avg
0.23
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | $43.82M | 0.04 | 0.07 | 0.10 | -0.55 |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.15M | 0.00 | 0.45 | 0.37 | 0.27 |
| DarioHealth Corp. (DRIO)vs › | $45.37M | 0.59 | 0.44 | 0.44 | 0.29 |
| Lite Strategy, Inc. (LITS)vs › | $47.01M | 0.00 | 0.00 | 0.13 | 0.14 |
| CVRx, Inc. (CVRX)vs › | $41.40M | 2.98 | 1.00 | 0.61 | 0.49 |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| Celularity Inc. (CELU)vs › | $48.63M | N/A | 4.70 | 2.51 | 1.98 |
| Clene Inc. (CLNN)vs › | $48.59M | N/A | 6.12 | 6.71 | 4.67 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | 0.34 | 0.23 | 0.23 | 0.23 |
| Microbot Medical Inc. (MBOT)vs › | $50.13M | 0.01 | 0.02 | 0.04 | 0.04 |
Debt/Equity
0.04
Current Ratio
0.98
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.04 |
| 2026-03-31 | 0.10 |
| 2025-12-31 | 0.09 |
| 2025-09-30 | 0.07 |
| 2025-06-30 | 0.07 |
| 2025-03-31 | 0.09 |
| 2024-12-31 | 0.11 |
| 2024-09-30 | 0.20 |
| 2024-06-30 | 0.25 |
| 2024-03-31 | 0.66 |
| 2023-12-31 | -3.51 |
| 2023-09-30 | -1.71 |
| 2023-06-30 | -1.11 |
| 2023-03-31 | -1.10 |
| 2022-12-31 | -1.25 |
| 2022-09-30 | -1.54 |
| 2022-06-30 | -1.71 |
| 2022-03-31 | -1.60 |
| 2021-12-31 | -0.82 |
| 2021-09-30 | -0.95 |
| 2021-06-30 | -0.93 |
| 2021-03-31 | -0.97 |
| 2020-12-31 | -0.97 |
| 2020-09-30 | -1.03 |
| 2020-06-30 | -1.15 |
| 2020-03-31 | -1.17 |
| 2019-12-31 | -1.25 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | -3.23 |
| 2018-09-30 | 4.60 |
| 2018-06-30 | 8.15 |
| 2018-03-31 | 0.92 |
| 2017-12-31 | 1.22 |
| 2017-09-30 | 0.72 |
| 2017-06-30 | 0.28 |
| 2017-03-31 | 0.26 |
| 2016-12-31 | 0.26 |
| 2016-09-30 | 1.09 |
| 2016-06-30 | 0.46 |
| 2016-03-31 | 0.43 |
| 2015-12-31 | 0.30 |
| 2015-09-30 | 0.05 |
| 2015-06-30 | 0.04 |
| 2015-03-31 | 0.03 |
| 2014-12-31 | -2.63 |
| 2014-09-30 | -2.97 |
| 2014-06-30 | 10.14 |
| 2014-03-31 | 0.43 |
| 2013-12-31 | 0.39 |
| 2013-09-30 | 0.26 |
| 2013-06-30 | 0.70 |
| 2013-03-31 | 0.47 |
